Infantile Krabbe Disease and Endpoints for Trials
Author Information
Author(s): Greco Melissa R., Lopez Mabel A., Beltran‐Quintero Maria L., Tuc Bengur Ecenur, Poe Michele D., Escolar Maria L.
Primary Institution: University of Pittsburgh
Hypothesis
The study aims to document disease progression in infantile-onset Krabbe disease and evaluate the outcomes of hematopoietic stem cell transplantation.
Conclusion
Infantile Krabbe disease with onset before 12 months is rapidly progressive, and timely HSCT is crucial to prevent irreversible brain damage.
Supporting Evidence
- Patients with symptomatic HSCT had a median survival of 5 years, while asymptomatic patients had a median survival of 15.5 years.
- Initial symptoms included irritability, developmental delay, and feeding difficulties.
- HSCT did not prevent the progression of peripheral nerve disease.
Takeaway
This study looks at babies with a rare disease called Krabbe disease and how a special treatment can help them live longer and feel better.
Methodology
Patients with infantile Krabbe disease were prospectively evaluated using standardized protocols and analyzed with descriptive statistics and Kaplan–Meier survival curves.
Potential Biases
Implicit bias may exist regarding the patients followed longitudinally, as those with less severe symptoms were more likely to be included.
Limitations
Challenges included obtaining outside medical records and ensuring longitudinal follow-up due to patient symptoms and other factors.
Participant Demographics
The study included 137 children (68 males and 69 females) with infantile Krabbe disease.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website